Recross Cardio Announces First Patient Enrolled in PROTEA-PFO US-Early Feasibility Study

Novel membrane-based PFO Sealing system designed to address limitations of current stroke prevention devices

NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Recross Cardio Inc., a structural heart company pioneering next-generation membrane sealing technology, today announces the first clinical implantation with its novel PFO Sealing system in the PROTEA-PFO Early Feasibility Study (EFS). The procedure was successfully performed by Dr. Carey Kimmelstiel and his interventional team at Tufts Medical Center in Boston, Massachusetts.